4 results
The primary objectives of this study are: * To characterize the effects of 150 mg and 450 mg of AT1001 administered 2 hours before administration of agalsidase on the safety and plasma pharmacokinetics of agalsidase in subjects with Fabry Disease*…
Our study tries to identify the ideal sclerosant dosage for the ClariVein® system in order to occlude the GSV permanently. By choosing the lowest dose with the same anatomical success rate, we achieve a safe treatment which also gives us the…
The purpose of this study is to compare the effect of AT1001 (migalastat hydrochloride) versus placebo on GL-3 in the kidney.
Objective: To evaluate the anatomical success of MOCA versus RFA in treatment of symptomatic insufficient SSV.